Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Rosnilimab (ANB030) in the Treatment of Subjects With Alopecia Areata

NCT05205070 is registered in ClinicalTrials.gov with AnaptysBio, Inc. as lead sponsor.

NCT NCT05205070
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05205070 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Rosnilimab (ANB030) in the Treatment of Subjects With Alopecia Areata
Lead sponsor
AnaptysBio, Inc.
Phase
Phase 2
Overall status
Unknown status
Start date
December 22, 2021
Completion date
March 19, 2023
Enrollment
45 (estimated)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

alopecia areata